TY - JOUR
T1 - Microneedles-Based Theranostic Platform
T2 - From the Past to the Future
AU - Li, Ziyang
AU - Wang, Yuhan
AU - Zhang, Ruiwei
AU - Liu, Zijian
AU - Chang, Ziyong
AU - Deng, Yulin
AU - Qi, Xiaoyue
N1 - Publisher Copyright:
© 2024 American Chemical Society.
PY - 2024/9/3
Y1 - 2024/9/3
N2 - Fully integrated theranostic devices are highly esteemed in clinical applications, offering immense potential in real-time disease monitoring and personalized care. Microneedles (MNs), as innovative and wearable devices, boast important advantages in biosensing and therapy, thus holding significant promise in the advancement of diagnostic and therapeutic platforms. Encouragingly, advancements in electrochemical sensing technology, micronano fabrication, and biocompatible materials are propelling momentum for MNs-based closed-loop systems, enhancing detection capabilities, biocompatibility, and cost-effectiveness. Moreover, the notable progress in integrating MN chips with other biochips signifies a frontier for growth. Successful clinical trials in target molecule monitoring and drug delivery domains herald excellent clinical translational prospects for the aforementioned theranostic platform. Finally, we delineate both challenges and opportunities in the development of integrated diagnostic and therapeutic MN systems, including continuous monitoring, intelligent control algorithms, safety, and regulatory considerations.
AB - Fully integrated theranostic devices are highly esteemed in clinical applications, offering immense potential in real-time disease monitoring and personalized care. Microneedles (MNs), as innovative and wearable devices, boast important advantages in biosensing and therapy, thus holding significant promise in the advancement of diagnostic and therapeutic platforms. Encouragingly, advancements in electrochemical sensing technology, micronano fabrication, and biocompatible materials are propelling momentum for MNs-based closed-loop systems, enhancing detection capabilities, biocompatibility, and cost-effectiveness. Moreover, the notable progress in integrating MN chips with other biochips signifies a frontier for growth. Successful clinical trials in target molecule monitoring and drug delivery domains herald excellent clinical translational prospects for the aforementioned theranostic platform. Finally, we delineate both challenges and opportunities in the development of integrated diagnostic and therapeutic MN systems, including continuous monitoring, intelligent control algorithms, safety, and regulatory considerations.
KW - closed-loop
KW - drug delivery
KW - interstitial fluid
KW - microneedles
KW - point-of-care diagnostics
KW - sensing
KW - theranostics
KW - wearable devices
UR - http://www.scopus.com/inward/record.url?scp=85202017553&partnerID=8YFLogxK
U2 - 10.1021/acsnano.4c04277
DO - 10.1021/acsnano.4c04277
M3 - Review article
AN - SCOPUS:85202017553
SN - 1936-0851
VL - 18
SP - 23876
EP - 23893
JO - ACS Nano
JF - ACS Nano
IS - 35
ER -